(0)サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1684318

薬剤統合ポリマー繊維の世界市場：種類別・用途別・治療適応症別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)

Drug Integrated Polymer Fibers Market, By Type, By Application, By Therapeutic Indication, By End-User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日
ページ情報
英文 301 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.05円
薬剤統合ポリマー繊維の世界市場：種類別・用途別・治療適応症別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2025年～2032年)
出版日: 2025年03月04日
発行: AnalystView Market Insights
ページ情報: 英文 301 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

薬剤統合ポリマー繊維市場は2024年に8,598万米ドルと評価され、2025年から2032年にかけてCAGR 5.90%で拡大

薬剤統合ポリマー繊維の市場力学

個別化医療に対する需要の高まりが市場成長に期待されます。

個別化医療は、個々の患者に特化した標的治療を促進することでドラッグデリバリーに革命をもたらし、それがポリマーベースのドラッグデリバリーシステムの使用を促進しています。薬剤を組み込んだポリマー繊維は、薬剤の制御された徐放を可能にし、それによって治療効果が各患者の固有のニーズに従って最適化されることを保証します。2023年、FDAは希少疾患患者を対象とした新たな個別化治療を16件承認したが、これは2022年の6件から大幅に増加しました。個別化医療連合が報告しているように、2023年に新たに承認された治療法のうち、がん治療薬が7つ、その他の疾患や症状に対応する治療薬が3つです。とはいえ、繊維製造技術の進歩は市場に成長機会をもたらす可能性があります。逆に、製造コストの高さが市場拡大を阻害する可能性もあります。

薬剤統合ポリマー繊維市場：主な考察

調査アナリストの分析によると、世界市場は予測期間（2025-2032年）にCAGR約5.90%で年間成長すると推定されます。

種類別では、ポリ乳酸（PLA）が2024年に最大市場シェアを示すと予測されています。

用途別では、整形外科用縫合糸が2024年の主要用途です。

地域別では、北米が2024年に収益を上げる主要市場です。

薬剤統合ポリマー繊維市場：セグメンテーション分析

薬剤統合ポリマー繊維の世界市場は、種類、用途、治療対象の適応症、エンドユーザー、地域に基づいて区分されます。

市場は種類によって3つのカテゴリーに分けられます：ポリ乳酸（PLA）、ポリジオキサノン（PDO）、ポリカプロラクトン（PCL）、その他（PGA、PLGA、PDLL）。ポリ乳酸（PLA）が市場をリードしています。ポリ乳酸（PLA）は生分解性で生体適合性のあるポリマーであり、薬物放出の制御のために繊維、フィルム、その他の形状に加工できることから、この市場で頻繁に使用されています。PLAはコーンスターチやサトウキビのような再生可能な資源に由来しており、環境に優しい選択肢となっています。生分解性があるため、体内で徐々に繊維が分解され、外科的除去の必要性を最小限に抑えることができます。

市場は用途によって5つのカテゴリーに分けられます：ドラッグデリバリー、整形外科用縫合糸、血管ステント、人工血管、皮膚創傷治癒、その他です。整形外科用縫合糸が市場を独占整形外科用縫合糸に関連する薬剤統合ポリマー繊維市場は、ポリマー繊維の生体適合性と、整形外科用途における効果的かつ局所的なドラッグデリバリーの必要性を組み合わせた、医療機器業界における有望かつ急速に発展している分野です。薬剤統合ポリマー繊維から作られた整形外科用縫合糸は、薬剤を手術部位に直接送達することで治癒を促進するよう設計されています。これは、骨や軟部組織の適切な治癒が長期的な回復に不可欠な整形外科手術において特に重要です。

市場は、治療対象の適応症に基づいて3つのカテゴリーに分けられます：がん、心血管疾患、呼吸器疾患です。技術の進歩に伴い、これらのファイバーはより洗練されたものとなり、薬物放出の制御や個別化された治療アプローチが可能になり、最終的には患者の転帰や生活の質を向上させることになります。これらの治療領域でドラッグデリバリーにポリマー繊維を使用する最も大きな利点のひとつは、局所的で的を絞った治療を提供でき、全身的な副作用を最小限に抑えられることです。薬剤統合ポリマー繊維の開発には、特に生体適合性、安全性、長期的有効性に関する厳しい規制要件を満たす必要があります。

市場はエンドユーザーによって製薬会社と医療機器メーカーの2つに分類されます。特に製薬会社や医療機器メーカーのようなエンドユーザーから見た薬剤統合ポリマー繊維市場は、より効果的で的を絞った治療のために高度なドラッグデリバリー技術を模索しているため、大きな成長を遂げています。両業界とも、患者の転帰を改善し、治療レジメンを最適化するために、薬剤統合ポリマー繊維の活用をますます進めています。

薬剤統合ポリマー繊維市場：地域別分析

北米が市場拡大をリードしているが、その主な要因は新興国の医療費の増加です。医療インフラと医療研究のための政府・民間両部門からの資金調達の増加は、薬剤統合ポリマー繊維の進歩と実装を促進します。米国医師会の報告によると、米国の医療費は2022年に4.1％増加し、4兆5,000億米ドルに達し、これは国民一人当たり1万3,493米ドルに相当します。この成長率はパンデミック以前の数字、具体的には2019年の4.1％と一致します。パンデミックへの対処を目的とした政府支出の結果、国民医療費（NHE）は大幅に増加したが、こうした費用は2021年には顕著な減少を見せ、医療品とサービスの利用が復活したのと一致しました。欧州は、ナノテクノロジーとエレクトロスピニング技術への投資の増加に起因して、市場成長において第2位の地域にランクされています。

薬剤統合ポリマー繊維市場：競合情勢

薬剤統合ポリマー繊維市場は、革新的な製品や高度なドラッグデリバリーシステムの開発を通じて市場シェアを獲得しようとする多数の有力企業によって特徴づけられるように、高いレベルの競争を示しています。この市場は、標的薬物デリバリーメカニズム、低侵襲医療機器、生体適合材料に対する需要の高まりによって成長を遂げています。この分野で事業を展開する企業は、医薬品の生体適合性と有効性を確保しつつ、持続的な薬物放出を可能にする高度なポリマー繊維の開発に専念しています。さらに、これらの企業は、製薬会社、バイオテクノロジー企業、学術機関との協力関係を確立し、製品開発の取り組みを強化するとともに、最先端技術へのアクセスを獲得しています。

目次

第1章 薬剤統合ポリマー繊維市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 薬剤統合ポリマー繊維の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 薬剤統合ポリマー繊維市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 薬剤統合ポリマー繊維市場：高まる地政学的緊張の影響

  • COVID-19パンデミックの影響
  • ロシア・ウクライナ戦争の影響
  • 中東紛争の影響

第6章 薬剤統合ポリマー繊維の市場情勢

  • 薬剤統合ポリマー繊維の市場シェア分析 (2024年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 薬剤統合ポリマー繊維市場：種類別

  • 概要
    • セグメント別シェア分析：種類別
    • ポリ乳酸（PLA）
    • ポリジオキサノン（PDO）
    • ポリカプロラクトン（PCL）
    • その他（PGA、PLGA、PDLL）

第8章 薬剤統合ポリマー繊維市場：用途別

  • 概要
    • セグメント別シェア分析：用途別
    • ドラッグデリバリー
    • 整形外科用縫合糸
    • 血管ステント
    • 血管移植
    • 皮膚創傷治癒
    • その他

第9章 薬剤統合ポリマー繊維市場：治療対象の適応症別

  • 概要
    • セグメント別シェア分析：治療対象の適応症別
    • がん
    • 心血管疾患
    • 呼吸器疾患

第10章 薬剤統合ポリマー繊維市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 製薬会社
    • 医療機器メーカー

第11章 薬剤統合ポリマー繊維市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • オランダ
    • スウェーデン
    • ロシア
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • インドネシア
    • タイ
    • フィリピン
    • その他
  • ラテンアメリカ（LATAM）
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東およびアフリカ（MEA）
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第12章 主要ベンダー分析：薬剤統合ポリマー繊維業界

  • 競合ダッシュボード
    • 競合ベンチマーク
    • 競合ポジショニング
  • 企業プロファイル
    • Asahi Kasei Corporation
    • Teijin Aramid
    • Toray Industries Inc.
    • Lycra（Invista）
    • Kaneka Corporation
    • Mitsubishi Chemical Corporation
    • Celanese Corporation
    • Teijin Limited
    • DuPont de
    • Nemours Inc.
    • Rhodia（Solvay）
    • Solvay SA
    • BASF SE
    • Sumitomo Chemical Company Limited
    • Evonik Industries AG
    • Kureha Corporation
    • Others

第13章 AnalystViewの全方位的分析

目次
Product Code: ANV4821

REPORT HIGHLIGHT

The Drug Integrated Polymer Fibers Market was valued at US$ 85.98 million in 2024 and expanded at a CAGR of 5.90% from 2025 to 2032.

Drug Integrated Polymer Fibers are advanced fibers composed of polymers that are infused with therapeutic agents to facilitate controlled and sustained drug release. These fibers are engineered to administer medications directly to targeted areas within the body or to distribute them throughout the system over an extended duration, thereby improving the efficacy and accuracy of medical treatments. Their applications are numerous, particularly within the medical and pharmaceutical sectors, where they serve purposes such as implantable drug delivery systems, wound management, and surgical sutures.

Drug Integrated Polymer Fibers Market- Market Dynamics

Rising Demand for Personalized Medicine is expected to the market growth.

Personalized medicine is revolutionizing drug delivery by facilitating targeted treatments that are specific to individual patients, which in turn is promoting the use of polymer-based drug delivery systems. Polymer fibers that incorporate drugs enable the controlled and sustained release of medications, thereby ensuring that therapeutic effects are optimized according to the unique needs of each patient. In 2023, the FDA approved 16 new personalized treatments aimed at patients with rare diseases, a significant increase from the six approvals in 2022. Among the newly approved treatments for 2023, there are seven drugs for cancer and three addressing other diseases and conditions, as reported by the Personalized Medicine Coalition. Nevertheless, advancements in fiber manufacturing technology may present growth opportunities for the market. Conversely, high manufacturing costs could impede market expansion.

Drug Integrated Polymer Fibers Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 5.90% over the forecast period (2025-2032)

Based on Type segmentation, Polylactic Acid (PLA) was predicted to show maximum market share in the year 2024

Based on application segmentation, Orthopedic Sutures was the leading application in 2024

Based on region, North America was the leading revenue generator in 2024

Drug Integrated Polymer Fibers Market- Segmentation Analysis:

The Global Drug Integrated Polymer Fibers Market is segmented based on Type, Application, Therapeutic Indication, End-User, and Region.

The market is divided into three categories based on Type: Polylactic Acid (PLA), Polydioxanone (PDO), Polycaprolactone (PCL), and Others (PGA, PLGA, and PDLL). Polylactic Acid (PLA) leads the market. Polylactic Acid (PLA), a biodegradable and biocompatible polymer, is frequently used in this market due to its ability to be processed into fibers, films, and other forms for controlled drug release. PLA is derived from renewable resources like cornstarch or sugarcane, making it an eco-friendly choice. Its biodegradability allows for the gradual breakdown of the fibers in the body, minimizing the need for surgical removal.

The market is divided into five categories based on application: Drug Delivery, Orthopedic Sutures, Vascular Stents, Vascular Grafts, Dermal Wound Healing, and Others. Orthopedic Sutures dominate the market. The Drug Integrated Polymer Fibers Market in the Context of Orthopedic Sutures represents a promising and rapidly evolving segment within the medical device industry, combining the biocompatibility of polymer fibers with the need for effective and localized drug delivery in orthopedic applications. Orthopedic sutures made from drug-integrated polymer fibers are designed to promote healing by delivering drugs directly to the surgical site. This is particularly important in orthopedic surgeries, where proper healing of bone and soft tissue is critical for long-term recovery.

The market is divided into three categories based on Therapeutic Indications: Cancer, Cardiovascular Diseases, and Respiratory Diseases. As technology advances, these fibers will become more sophisticated, allowing for better-controlled drug release and personalized treatment approaches, ultimately improving patient outcomes and quality of life. One of the most significant advantages of using polymer fibers for drug delivery in these therapeutic areas is the ability to provide localized and targeted treatment, minimizing systemic side effects. The development of drug-integrated polymer fibers must meet rigorous regulatory requirements, particularly regarding biocompatibility, safety, and long-term efficacy.

The market is divided into two categories based on End-User: Pharmaceutical Companies and Medical Device Manufacturers. The Drug Integrated Polymer Fibers Market, particularly from the perspective of end-users like Pharmaceutical Companies and Medical Device Manufacturers, is experiencing significant growth as these sectors explore advanced drug delivery technologies for more effective and targeted therapies. Both industries are increasingly leveraging drug-integrated polymer fibers to improve patient outcomes and optimize treatment regimens.

Drug Integrated Polymer Fibers Market- Geographical Insights

North America leads the market expansion, primarily driven by the increasing healthcare expenditures in emerging economies. The rise in funding from both government and private sectors for healthcare infrastructure and medical research facilitates the advancement and implementation of drug-integrated polymer fibers. As reported by the American Medical Association, health spending in the United States rose by 4.1% in 2022, reaching USD 4.5 trillion, which translates to USD 13,493 per capita. This growth rate aligns with pre-pandemic figures, specifically 4.1% in 2019. While government expenditures aimed at managing the pandemic resulted in significant increases in National Health Expenditure (NHE), these costs saw a notable decline in 2021, coinciding with a resurgence in the utilization of medical goods and services. Europe ranks as the second-largest region for market growth, attributed to the increasing investments in nanotechnology and electrospinning techniques.

Drug Integrated Polymer Fibers Market- Competitive Landscape:

The Drug Integrated Polymer Fibers Market exhibits a high level of competition, characterized by numerous prominent entities striving to capture market share through the creation of innovative products and sophisticated drug delivery systems. This market is experiencing growth driven by the rising demand for targeted drug delivery mechanisms, minimally invasive medical devices, and biocompatible materials. Firms operating in this sector are dedicated to the development of advanced polymer fibers capable of providing sustained drug release while ensuring the biocompatibility and efficacy of pharmaceuticals. Additionally, these companies are establishing collaborations with pharmaceutical organizations, biotechnology firms, and academic institutions to bolster their product development efforts and gain access to state-of-the-art technologies.

Recent Developments:

On June 25, 2024, Medical products, including ointments and syringes, encountered challenges in providing localized medication delivery, particularly in a controlled manner over extended durations. In response to this issue, researchers at Empa are innovating polymer fibers designed to deliver active ingredients with precision over prolonged periods. These liquid core fibers encapsulate pharmaceuticals and can be integrated into medical textiles.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Asahi Kasei Corporation
  • Teijin Aramid
  • Toray Industries Inc.
  • Lycra (Invista)
  • Kaneka Corporation
  • Mitsubishi Chemical Corporation
  • Celanese Corporation
  • Teijin Limited
  • DuPont de
  • Nemours Inc.
  • Rhodia (Solvay)
  • Solvay S.A.
  • BASF SE
  • Sumitomo Chemical Company Limited
  • Evonik Industries AG
  • Kureha Corporation
  • Others

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Polylactic Acid (PLA)
  • Polydioxanone (PDO)
  • Polycaprolactone (PCL)
  • Others (PGA, PLGA and PDLL)

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Drug Delivery
  • Orthopedic Sutures
  • Vascular Stents
  • Vascular Grafts
  • Dermal Wound Healing
  • Others

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY THERAPEUTIC INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Cancer
  • Cardiovascular Diseases
  • Respiratory Diseases

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical Companies
  • Medical Device Manufacturers

GLOBAL DRUG INTEGRATED POLYMER FIBERS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Drug Integrated Polymer Fibers Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Drug Integrated Polymer Fibers Market Snippet by Type
    • 2.1.2. Drug Integrated Polymer Fibers Market Snippet by Application
    • 2.1.3. Drug Integrated Polymer Fibers Market Snippet by Therapeutic Indication
    • 2.1.4. Drug Integrated Polymer Fibers Market Snippet by End-User
    • 2.1.5. Drug Integrated Polymer Fibers Market Snippet by Country
    • 2.1.6. Drug Integrated Polymer Fibers Market Snippet by Region
  • 2.2. Competitive Insights

3. Drug Integrated Polymer Fibers Key Market Trends

  • 3.1. Drug Integrated Polymer Fibers Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Drug Integrated Polymer Fibers Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Drug Integrated Polymer Fibers Market Opportunities
  • 3.4. Drug Integrated Polymer Fibers Market Future Trends

4. Drug Integrated Polymer Fibers Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Drug Integrated Polymer Fibers Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Drug Integrated Polymer Fibers Market Landscape

  • 6.1. Drug Integrated Polymer Fibers Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Drug Integrated Polymer Fibers Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. Polylactic Acid (PLA)
    • 7.1.3. Polydioxanone (PDO)
    • 7.1.4. Polycaprolactone (PCL)
    • 7.1.5. Others (PGA, PLGA and PDLL)

8. Drug Integrated Polymer Fibers Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Drug Delivery
    • 8.1.3. Orthopedic Sutures
    • 8.1.4. Vascular Stents
    • 8.1.5. Vascular Grafts
    • 8.1.6. Dermal Wound Healing
    • 8.1.7. Others

9. Drug Integrated Polymer Fibers Market - By Therapeutic Indication

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Indication, 2024 & 2032 (%)
    • 9.1.2. Cancer
    • 9.1.3. Cardiovascular Diseases
    • 9.1.4. Respiratory Diseases

10. Drug Integrated Polymer Fibers Market - By End-User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End-User, 2024 & 2032 (%)
    • 10.1.2. Pharmaceutical Companies
    • 10.1.3. Medical Device Manufacturers

11. Drug Integrated Polymer Fibers Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Drug Integrated Polymer Fibers Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Drug Integrated Polymer Fibers Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Drug Integrated Polymer Fibers Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Drug Integrated Polymer Fibers Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Drug Integrated Polymer Fibers Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Therapeutic Indication, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End-User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Drug Integrated Polymer Fibers Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Asahi Kasei Corporation
    • 12.2.2. Teijin Aramid
    • 12.2.3. Toray Industries Inc.
    • 12.2.4. Lycra (Invista)
    • 12.2.5. Kaneka Corporation
    • 12.2.6. Mitsubishi Chemical Corporation
    • 12.2.7. Celanese Corporation
    • 12.2.8. Teijin Limited
    • 12.2.9. DuPont de
    • 12.2.10. Nemours Inc.
    • 12.2.11. Rhodia (Solvay)
    • 12.2.12. Solvay S.A.
    • 12.2.13. BASF SE
    • 12.2.14. Sumitomo Chemical Company Limited
    • 12.2.15. Evonik Industries AG
    • 12.2.16. Kureha Corporation
    • 12.2.17. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us